Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinomaa multicentre phase I study

European Journal of Cancer

Volumn 36, Issue 6, 2000, Pages 742-747

  Giannakakis, T ^a   Ziras, N ^a   Kakolyris, S ^b   Mavroudis, D ^b   Androulakis, N ^b   Agelaki, S ^b   Parashos, M ^a   Sarra, E ^b   Dimou, Th ^c   Hatzidaki, D ^b   Vlachonikolis, J ^d   Georgoulias, V ^b  

^a AGII ANARGIRI CANCER HOSPITAL   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c UNIVERSITY GENERAL HOSPITAL OF PATRAS   (Greece)

^d UNIVERSITY OF CRETE   (Greece)

Author keywords

Carboplatin; Docetaxel; NSCLC; Phase I

Indexed keywords

CARBOPLATIN; DOCETAXEL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEBRILE NEUTROPENIA; FLUID RETENTION; HUMAN; LUNG NON SMALL CELL CANCER; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOLOGIC DISEASES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; TAXOIDS;

EID: 0034126930     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00005-8     Document Type: Article

References (30)

1. Non-Small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer. a meta-analysis using updated data on individual patients Br. Med. J. 311:1995;899-909.
2. Depierre A., Lemarie E., Dabuis G., Garnier G., Jacoulet P., Dalphin J.C. A phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am. J. Clin. Oncol. 14:1991;115-119.
3. Rowinsky E.K., Donehower R.C. Paclitaxel (Taxol). N. Engl. J. Med. 332:1995;1004-1014.
4. Abratt R.P., Bezwoda W.R., Falkson G., Goedhals L., Hacking D., Rugg T.A. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer. a phase II study J. Clin. Oncol. 12:1994;1535-1540.
5. Anderson H., Lund B., Bach F., Thatcher N., Walling J., Hansen H.H. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer. a phase II study J. Clin. Oncol. 12:1994;1821-1826.
6. Francis P.A., Rigas J.R., Kris M.G.et al. Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J. Clin. Oncol. 12:1994;1232-1237.
7. 2 docetaxel with prednisone premedication in patients with advanced non-small cell lung cancer. Cancer. 75:1995;968-972.
8. Cerny T., Kaplan S., Pavlidis N.et al. Docetaxel (Taxotere) is active in non-small cell lung cancer. a phase II trial of the EORTC Early Clinical Trials Group (ECTG) Br. J. Cancer. 70:1994;384-387.
9. Burris HA, Eckardt J, Fields S, et al. Phase II trial of Taxotere in patients with non-small cell lung cancer. Proc Am Soc Clin Oncol 1993, 12, 335 (abstract 1116).
10. Fossella F.V., Lee J.S., Murphy W.K.et al. Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J. Clin. Oncol. 12:1994;1238-1244.
11. Gandara DR, Vokes E, Green M, et al. Docetaxel (Taxotere) in platinum-treated non-small-cell lung cancer (NSCLC): confirmation of prolonged survival in a multicenter trial. Proc Am Soc Clin Oncol 1997, 16, 454a (abstract 1632).
12. Alexopoulos K., Kouroussis Ch., Androulakis N.et al. Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy. a multicenter phase II trial Cancer Chemother. Pharmacol. 43(3):1999;257-262.
13. Berille J., Le Chevalier T., Zalcberg J.R.et al. Overview on Taxotere-cisplatin (TXT-CDDP) combination in non-small-cell lung cancer (NSCLC). Meeting of the European Society of Medical Oncology, Vienna. Ann. Oncol. 7(Suppl. 5):1996;90.
14. Georgoulias V., Androulakis N., Dimopoulos A.M.et al. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin. a multicenter phase II study Ann. Oncol. 9:1998;331-334.
15. Bonomi P.D., Finkelstein D.M., Ruckdeschel J.C.et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer. a study of the Eastern Cooperative Oncology Group J. Clin. Oncol. 7:1989;1602-1613.
16. Calvert A.H., Harland S.J., Newell D.R.et al. Early clinical studies with cis-diammine-1, 1-cyclobutane-dicarboxylate platinum II. Cancer Chemother. Pharmacol. 9:1982;140-147.
17. Curt G.A., Grygeil J.J., Corden B.J.et al. A phase I and pharmacokinetic study of diammine-cyclobutane-decarboxylate-platinum (NSC 241240). Cancer Res. 43:1983;4470-4473.
18. Langer C.J., Leighton J.C., Comis R.L.et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer. a phase II toxicity, response, and survival analysis J. Clin. Oncol. 13:1995;1860-1870.
19. Johnson D.H., Paul D.M., Hande K.R.et al. Paclitaxel plus carboplatin in advanced non-small-call lung cancer. a phase II trial J. Clin. Oncol. 14:1996;2054-2060.
20. Bunn P.A. The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer. Semin. Oncol. 231(Suppl. 16):1996;18-25.
21. Kosmidis P.A., Mylonakis N., Fountzilas G.et al. Paclitaxel and carboplatin in inoperable non-small-cell lung cancer. a phase II study Ann. Oncol. 8:1997;697-699.
22. Macha HN, Gatzemeier U, Betticher DC, et al. Randomized multicenter trial comparing paclitaxel (TAX)/carboplatin (CAR) versus paclitaxel/cisplatin (CIS) in advanced non-small cell lung cancer (NSCLC): results of a planned interim analysis. Proc Am Soc Clin Oncol 1998, 17 465a (abstract 1789).
23. Miller A.B., Hoogstraten B.B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
24. Kouroussis Ch., Androulakis N., Kakolyris S.et al. Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer. J. Clin. Oncol. 17:1999;862-869.
25. Calvert A.H., Newell D.R., Gumbrell L.A.et al. Carboplatin dosage. prospective evaluation of a simple formula based on renal function J. Clin. Oncol. 7:1989;1748-1756.
26. Vasey PA, Atkinson R, Coleman R, et al. Dose-finding study of docetaxel-carboplatin in untreated advanced epithelial ovarian cancer (EOC). Ann Oncol 1998, 9(Suppl. 4), (abstract 66).
27. Belani CP, Hadeed V, Ramanathan R, et al. Docetaxel and carboplatin: a phase I and pharmacokinetic trial of advanced non-hematologic malignancies. Proc Am Soc Clin Oncol 1997, 16, 220a (abstract 771).
28. Belani C.P. Paclitaxel/carboplatin in the treatment of non-small cell lung cancer. Oncology. 12(Suppl. 20):1998;74-79.
29. Langer C, McAleer C, Millenson M, et al. Phase I evaluation of docetaxel (D) and carboplatin (C) in advanced malignancy: stratification of patient cohorts based on prior treatment (Tx) status yields useful results. Proc Am Soc Clin Oncol 1998, 17, 204a (abstract 787).
30. Kearns CM, Belani CP, Erkmen K, et al. Reduced platelet toxicity with a combination of carboplatin and paclitaxel: pharmacodynamic modulation of carboplatin-associated thrombocytopenia. Proc Am Soc Clin Oncol 1995, 14, 170 (abstract 364).